Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Behringwerke AG, a subsidiary of Sanofi, is a German company located in Marburg. The firm produces specialty chemicals and pharmaceutical products.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Dong Wha Pharm Co., Ltd. engages in the manufacture and sale of pharmaceuticals and medicinal chemicals. Its products include medicines for digestion, skin scars, general cold, gum treatment, high blood pressure, infection, gastrointestinal tract control, and others. The company was founded on September 25, 1897 and is headquartered in Seoul, South Korea.

Medikan Co., Ltd. is a private company headquartered in Seoul, the South Korea. The firm manufactures surgical and medical devices. It was founded in 1996. Hee Young Lee is currently the CEO of the company.

Chengdu Wesker Biopharmaceutical Co., Ltd., established on 2020-07-14, Business scope includes licensed projects:Drug import and export;Technology Import and Export;Import and export;pharmaceutical production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Nanjing Tianbang Bio Technology Co., Ltd., part of Beijing Dabeinong Technology Group Co., Ltd., is a Chinese company located in Nanjing. The firm engages in researching and developing animal bio products. On March 12, 2014 Beijing Dabeinong Technology Group Co., Ltd. acquired Nanjing Tianbang Bio Technology Co., Ltd. for $1.94 million.

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Qilu Animal Health Products Co., Ltd., established on 1987-04-20, Business scope includes general items:Feed Additive Sales;Animal Husbandry and Fishery Feed Sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Veterinary drug production;Veterinary drug business;Drug import and export;feed production;Feed additive production;road freight transport(Does not contain dangerous goods)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna. It employs 400 people in Austria, Scotland and the United States.

CJ Corporation (Korean: 씨제이㈜) is a South Korean conglomerate holding company headquartered in Seoul. It comprises numerous businesses in various industries of food and food service, pharmaceutics and biotechnology, entertainment and media, home shopping and logistics. CJ Group was originally a branch of Samsung until it separated in the 1990s.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Denka Seiken started out as a manufacturer of vaccines for human use. Later, they became involved with diagnostic reagents and expanded the scope of their business activities to meet the needs of their customers, offering product lines, service, and knowledge to hospitals and clinics. Denka Seiken has established itself as a manufacturer of vaccines and diagnostic reagents.\nDenka Seiken is engaged in research and development in such fields as bacteriology and virology, immunochemistry, clinical chemistry and food-related diagnostic reagents, in addition to vaccines against influenza, DPT, and other illnesses.

Green Cross Co., Ltd. engages in the manufacture, sale, and rental of safety items. Its products include road safety materials, disaster prevention necessities, safety equipment, protection gear, and signboards and tags. The company was founded in January 1969 and is headquartered in Fukuoka, Japan.